

Rachel Wade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9724653/publications.pdf>

Version: 2024-02-01

40
papers

2,812
citations

257101

24
h-index

288905

40
g-index

41
all docs

41
docs citations

41
times ranked

3936
citing authors

#	ARTICLE	IF	CITATIONS
1	Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 730-738.	0.8	8
2	Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 4228-4239.	0.8	8
3	Body mass index and COVID-19 mortality: prospective study of 120 000 Mexican adults. <i>International Journal of Epidemiology</i> , 2022, 51, 1698-1700.	0.9	2
4	Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150 000 adults. <i>International Journal of Epidemiology</i> , 2021, 50, 955-964.	0.9	11
5	Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998–2004 and 2015–2019. <i>Diabetes Care</i> , 2021, 44, 944-951.	4.3	6
6	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2828-2839.	1.8	10
7	Association of Blood Pressure With Cause-Specific Mortality in Mexican Adults. <i>JAMA Network Open</i> , 2020, 3, e2018141.	2.8	6
8	General and Abdominal Adiposity and Mortality in Mexico City. <i>Annals of Internal Medicine</i> , 2019, 171, 397.	2.0	21
9	Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 455-463.	5.5	50
10	Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 34-43.	0.8	147
11	Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 660-667.	0.8	76
12	Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. <i>British Journal of Haematology</i> , 2016, 172, 439-451.	1.2	68
13	The long-term outcome of patients in the LRF CLL 4 trial: the effect of salvage treatment and biological markers in those surviving 10 years. <i>British Journal of Haematology</i> , 2016, 172, 228-237.	1.2	12
14	Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997–2003. <i>Archives of Disease in Childhood</i> , 2016, 101, 449-454.	1.0	22
15	Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL 2003. <i>British Journal of Haematology</i> , 2015, 170, 550-558.	1.2	20
16	Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. <i>British Journal of Haematology</i> , 2015, 169, 228-240.	1.2	41
17	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 1434-1444.	0.6	178
18	Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. <i>Blood</i> , 2014, 124, 1056-1061.	0.6	186

#	ARTICLE	IF	CITATIONS
19	Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. <i>British Journal of Haematology</i> , 2014, 165, 552-555.	1.2	38
20	Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. <i>British Journal of Haematology</i> , 2014, 166, 421-424.	1.2	196
21	<i>t(12;21)(p13;p21)</i> Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. <i>Journal of Clinical Oncology</i> , 2014, 32, 1453-1462.	0.8	87
22	Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 809-818.	5.1	270
23	The clinical significance of patients' sex in chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 1088-1094.	1.7	55
24	Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 199-209.	5.1	407
25	Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. <i>British Journal of Haematology</i> , 2013, 162, 710-713.	1.2	40
26	Thiopurine methyltransferase genotype phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 125-136.	1.1	48
27	Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration. <i>Clinical Cancer Research</i> , 2012, 18, 4191-4200.	3.2	30
28	Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 1289-1298.	0.6	28
29	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 843-846.	0.6	76
30	Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2223-2229.	0.8	235
31	No association of HLA supertype with outcome in childhood acute lymphoblastic leukaemia: results of the UKALL XI trial. <i>British Journal of Haematology</i> , 2011, 153, 131-133.	1.2	1
32	Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. <i>Haematologica</i> , 2011, 96, 1496-1503.	1.7	20
33	Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. <i>Haematologica</i> , 2010, 95, 1705-1712.	1.7	116
34	Relationship between HLA supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?. <i>British Journal of Haematology</i> , 2009, 145, 87-95.	1.2	7
35	Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. <i>British Journal of Haematology</i> , 2009, 146, 384-395.	1.2	20
36	The impact of risk stratification by early bone marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. <i>British Journal of Haematology</i> , 2009, 146, 424-436.	1.2	56

#	ARTICLE	IF	CITATIONS
37	Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. <i>British Journal of Haematology</i> , 2008, 143, 690-697.	1.2	45
38	Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. <i>Blood</i> , 2008, 111, 1625-1633.	0.6	31
39	The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. <i>Blood</i> , 2008, 111, 1820-1826.	0.6	120
40	Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003.. <i>Blood</i> , 2008, 112, 908-908.	0.6	6